The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis.
 
Helen Ajufo
No Relationships to Disclose
 
Jan Philipp Bewersdorf
No Relationships to Disclose
 
Claire Harrison
Honoraria - Abbvie; CTI BioPharma Corp; Geron; Janssen; Novartis
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Celgene; Constellation Pharmaceuticals; CTI; Galecto; Geron; Gilead Sciences; Janssen; Keros Therapeutics; Novartis; Promedior; Roche; Shire; Sierra Oncology
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; Novartis; Sierra Oncology
Research Funding - Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Novartis (Inst)
 
Francesca Palandri
Honoraria - AOP Orphan Pharmaceuticals; Celgene; CTI; Novartis; Sierra Oncology
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Celgene; CTI; Novartis; Sierra Oncology
 
John Mascarenhas
Consulting or Advisory Role - Abbvie; Constellation Pharmaceuticals; CTI BioPharma Corp; Galecto; Geron; Incyte; Kartos Therapeutics; Karyopharm Therapeutics; Novartis; Pharmaessentia; Roche/Genentech; Sierra Oncology
Research Funding - Abbvie (Inst); Celgene/Bristol-Myers Squibb (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pharmaessentia (Inst); Roche/Genentech (Inst)
 
Jeanne M. Palmer
Honoraria - CTI BioPharma Corp
Consulting or Advisory Role - CTI BioPharma Corp; PharmaEssentia; Protagonist Therapeutics; Sierra Oncology
Research Funding - PharmaEssentia (Inst)
 
Aaron Thomas Gerds
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb/Celgene; CTI BioPharma Corp; MorphoSys; Novartis; PharmaEssentia; Sierra Oncology
Research Funding - Accurate Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Imago BioSciences (Inst); Incyte (Inst); Kartos Therapeutics (Inst); MorphoSys (Inst)
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; Incyte; Novartis
 
Andriy Derkach
No Relationships to Disclose
 
Raajit Rampal
Honoraria - Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Constellation Pharmaceuticals; CTI BioPharma Corp; Disc Medicine; Galecto; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia; Promedior; SERVIER; Sierra Oncology; Stemline Therapeutics; Sunimoto Dainippon; Zentalis
Research Funding - Constellation Pharmaceuticals; Ryvu Therapeutics; Stemline Therapeutics; Zentalis
Travel, Accommodations, Expenses - Incyte; Sierra Oncology
 
Sarah Buckley
Employment - CTI BioPharma Corp
Stock and Other Ownership Interests - CTI BioPharma Corp
 
Karisse Roman-Torres
Employment - CTI BioPharma Corp
Stock and Other Ownership Interests - CTI BioPharma Corp